Amoscanate manufacturers
- Amoscanate
-
- $76.00
-
2026-05-11
- CAS:26328-53-0
- Purity:
- Supply Ability: 10g
- Amoscanate USP/EP/BP
-
- $1.10
-
2025-11-18
- CAS:26328-53-0
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons Min
|
| | Amoscanate Basic information |
| Product Name: | Amoscanate | | Synonyms: | 4-Isothiocyanato-N-(4-nitrophenyl)benzenamine;C-9333 GO;CGP-4540;CIBA-9333 GO;Nithiocyamine;4-Nitro-4'-iso-thiocyanate diphenyl amine;Benzenamine, 4-isothiocyanato-N-(4-nitrophenyl)-;amoscanate USP/EP/BP | | CAS: | 26328-53-0 | | MF: | C13H9N3O2S | | MW: | 271.29 | | EINECS: | | | Product Categories: | | | Mol File: | 26328-53-0.mol |  |
| | Amoscanate Chemical Properties |
| Melting point | 196-198° | | Boiling point | 469.7±30.0 °C(Predicted) | | density | 1.3474 (rough estimate) | | refractive index | 1.6740 (estimate) | | pka | -3.50±0.40(Predicted) | | form | Solid | | color | Crystals from acetone |
| Toxicity | dnr-esc 1 g/L MUREAV 164,9,86 |
| | Amoscanate Usage And Synthesis |
| Chemical Properties | Orange-yellow crystalline powder, odorless and tasteless. Melting point 196-198°C. Insoluble in water, slightly soluble in acetone, chloroform, benzene and ethanol. | | Uses | Amoscanate (cgp4540) is phenyl isothiocyanate in which the hydrogen at the para-position has been replaced by a 4-nitroanilinyl group. Amoscanate is an anti-schistosomal agent. Amoscanate, as an isothiocyanate compound and uncoupler of oxidative phosphorylation, potently injures rodent ependyma[1]. | | Definition | ChEBI: Amoscanate is an isothiocyanate that is phenyl isothiocyanate in which the hydrogen at the para- position has been replaced by a 4-nitroanilinyl group. It has a role as a schistosomicide drug. It is a C-nitro compound, an isothiocyanate and a secondary amino compound. It is functionally related to a diphenylamine. | | Safety Profile | Mutation data reported. Ananthelmintic agent. | | in vivo | Amoscanate (500 mg/kg; p.o.; 10 days) destructs ependyma and periventricular brain[1].
Amoscanate (250 and 500 mg/kg; p.o.; 28 days) elicits necrosis, Ca++-positive microgranules, pyknosis and edema localized in ependyma/subependyma in the medial striatum[1].
Amoscanate (25~500 mg/kg; p.o.; 20 days) elicits progressive necrosis of ependyma[1].
Amoscanate elicits massive ultrastructural damage in ependymal cells[1]. | Animal Model: | Sprague-Dawley rats[1] | | Dosage: | 500 mg/kg | | Administration: | P.o.; 10 days | | Result: | Destructed ependyma and periventricular brain.
|
| Animal Model: | Sprague-Dawley rats[1] | | Dosage: | 250 and 500 mg/kg | | Administration: | P.o.; 28 days | | Result: | Elicited necrosis, Ca++-positive microgranules, pyknosis and edema localized in ependyma/subependyma in the medial striatum.
|
| Animal Model: | Sprague-Dawley rats[1] | | Dosage: | 25~500 mg/kg | | Administration: | P.o.; 20 days | | Result: | Elicited progressive necrosis of ependymal.
|
| | IC 50 | Schistosome | | References | [1] Johanson C, et al. The distributional nexus of choroid plexus to cerebrospinal fluid, ependyma and brain: toxicologic/pathologic phenomena, periventricular destabilization, and lesion spread. Toxicol Pathol. 2011;39(1):186-212. DOI:10.1177/0192623310394214 |
| | Amoscanate Preparation Products And Raw materials |
|